T1	Cluster1 0 41	Familial amyloidotic polyneuropathy (FAP)
T2	Entity 45 69	a hereditary amyloidosis
T3	Entity 81 115	amyloidogenic transthyretin (ATTR)
T4	Entity 162 173	synthesized
T5	Entity 177 186	the liver
T6	Entity 70 77	induced
T7	Entity 256 260	halt
T8	Cluster2 297 299	LT
T9	Entity 319 335	several problems
T10	Cluster2 388 390	LT
T11	Entity 520 533	The induction
T12	Entity 537 573	induced pluripotent stem (iPS) cells
T13	Cluster10 632 640	patients
T14	Entity 723 732	elucidate
T15	Entity 984 1002	dermal fibroblasts
T16	Entity 974 983	reprogram
T17	Entity 871 900	a Sendai virus vector mixture
T18	Cluster6 1103 1124	hepatocyte-like cells
T19	Entity 1136 1150	expressed ATTR
T20	Entity 1084 1097	differentiate
T21	Cluster5 1218 1237	a pathological tool
T22	Cluster11 1416 1430	a Sendai virus
T23	Cluster6 1494 1515	hepatocyte-like cells
T24	Entity 1475 1488	differentiate
T25	Cluster6 1519 1540	Hepatocyte-like cells
T26	Cluster5 1666 1685	a pathological tool
T27	Cluster2 188 214	liver transplantation (LT)
T28	Entity 261 283	the progression of FAP
T29	Entity 125 158	most transthyretin (TTR) in serum
T30	Entity 601 618	pluripotent cells
T31	Entity 673 687	human diseases
T32	Entity 805 839	heterozygous ATTR mutant iPS cells
T33	Cluster10 1016 1028	FAP patients
T34	Cluster3 1040 1062	FAP-specific iPS cells
T35	Cluster3 1152 1174	FAP-specific iPS cells
T36	Entity 1319 1333	FAP treatments
T37	Cluster3 1384 1406	FAP-specific iPS cells
T38	Cluster3 1434 1456	FAP-specific iPS cells
T39	Cluster3 1546 1568	FAP-specific iPS cells
T40	Cluster3 1603 1625	FAP-specific iPS cells
T41	Entity 733 759	the molecular pathogenesis
T42	Cluster1 763 766	FAP
T43	Entity 912 970	four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc)
T44	Entity 1276 1292	the pathogenesis
T45	Cluster1 1296 1299	FAP
T46	Entity 1576 1599	expressed ATTR Val30Met
T47	Entity 501 509	patients
T48	Cluster1 515 518	FAP
T49	Entity 392 417	the detailed pathogenesis
T50	Cluster1 421 424	FAP
T51	Entity 475 497	the relevant processes
T52	Entity 586 597	development
T53	Entity 656 669	useful models
T54	Entity 1003 1010	derived
T55	Cluster9 782 784	we
T56	Cluster10 501 518	patients with FAP
T57	Cluster5 1238 1242	that
T58	Cluster9 1348 1350	We
T59	Cluster11 871 970	a Sendai virus vector mixture containing four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc)
T60	Cluster12 392 424	the detailed pathogenesis of FAP
T61	Cluster12 1276 1299	the pathogenesis of FAP
